. 2021 Nov 11;65(6):821–831. doi: 10.20945/2359-3997000000419

Table 1. Analysis the effects of interdisciplinary therapy on anthropometric and metabolic profile according FGF21 response.

	All sample (n = 31)		Increased FGF21 group (n = 16)		decreased FGF21 group (n=15)
	Baseline	After intervention	Baseline	After intervention	Baseline	After intervention
Body weight (kg)	89.73 ± 9.02	86.54 ± 9.04^a	88.35 ± 8.84	85.67 ± 8.78^a	91.20 ± 9.27	87.46 ± 9.53^a
Body mass index (kg/m²)^*	33.64 ± 3.49	32.44 ± 3.48	32.61 ± 3.97	31.62 ± 3.88	34.74 ± 2.60	33.31 ± 2.87
Neck circumference (cm)	35.94 ± 1.53	35.07 ± 1.39^a	35.78 ± 1.49	34.84 ± 1.28^a	36.11 ± 1.60	35.33 ± 1.52^a
Waist circumference (cm)	93.91 ± 7.14	90.10 ± 6.12^a	91.78 ± 6.53	88.39 ± 6.19^a	96.19 ± 7.26	92.08 ± 5.62^a
Abdominal circumference (cm)	106.93 ± 8.14	103.19 ± 7.51^a	105.79 ± 8.17	101.51 ± 7.13^a	108.13 ± 8.21	105.14 ± 7.74^a
Hip circumference (cm)	120.22 ± 8.03	117.34 ± 7.93^a	119.22 ± 8.85	117.01 ± 8.50	121.29 ± 7.20	117.72 ± 7.54^a
Body fat mass (%)^*	37.44 ± 4.37	35.75 ± 4.52	36.74 ± 4.57	35.12 ± 4.75	38.17 ± 4.17	36.43 ± 4.32
Body lean mass (kg)^*	56.48 ± 4.86	55.72 ± 4.55	56.73 ± 5.39	55.70 ± 5.07	56.22 ± 4.39	55.73 ± 4.16
Glucose (mg/dL)^*	93.10 ± 10.61	93.52 ± 7.15	89.75 ± 6.94	92.25 ± 6.74	96.67 ± 12.77^b	94.87 ± 7.56
Insulin (μU/mL)^*	10.83 ± 4.61	10.28 ± 4.36	10.33 ± 4.12	10.45 ± 3.93	11.36 ± 5.18	10.11 ± 4.88
HOMA-IR	2.51 ± 1.23	2.38 ± 1.01	2.32 ± 1.09	2.39 ± 0.90	2.72 ± 1.37	2.37 ± 1.14
HOMA-AD	0.89 ± 0.85	0.53 ± 0.30	0.86 ± 0.80	0.50 ± 0.23	0.91 ± 0.93	0.55 ± 0.35
Adiponectin (pg/mL)	3.78 ± 1.54	5.04 ± 2.04^a	3.44 ± 1.25	5.34 ± 2.38^a	4.11 ± 1.76	4.74 ± 1.68
Leptin (ng/mL)	51.48 ± 18.20	37.00 ± 14.22^a	56.46 ± 17.12	36.03 ± 13.75^a	46.50 ± 18.45	37.97 ± 15.09^a
Adiponectin/leptin	0.08 ± 0.04	0.15 ± 0.09^a	0.06 ± 0.03	0.17 ± 0.011^a	0.09 ± 0.05	0.14 ± 0.06
ANP (pg/mL)^*	373.18 ± 290.21	349.80 ± 313.17^a	353.34 ± 203.10	384.64 ± 363.58	391.59 ± 360.01	309.59 ± 251.34^a
FGF21 (pg/mL)	74.32 ± 44.15	127.89 ± 151.55^a	68.68 ± 50.11	197.86 ± 185.71^a	80.33 ± 37.58	53.26 ± 26.49^c

HOMA-IR: homeostasis model assessment-insulin resistance; HOMA-AD: HOMA-adiponectin; ANP: atrial natriuretic peptide; FGF21: human fibroblast growth factor 21.

Statistical difference between baseline and after intervention condition in the same group.

Statistical difference between groups in baseline condition.

Statistical difference between groups in after intervention condition.

Non-parametric data normalized by Z-score.

ANOVA two-way followed by Fisher post hoc test.

T-test for dependent sample.